Webinar: TRANSFORMING DRUG DISCOVERY BY JOINING THE DOTS

Presented by

DR ALLAN R. MOORMAN,

Senior Director of Medicinal Chemistry for King Pharmaceuticals Research and Development

Dr. Allan R. Moorman received his B.S. in Pharmacy followed by a Ph.D. in Medicinal Chemistry from the University of Kansas. Following a postdoctoral fellowship in Mechanistic Enzymology, he has spent the past 27 years in various industrial positions of growing responsibility. He is currently Senior Director of Medicinal Chemistry for King Pharmaceuticals Research and Development where he has responsibility for drug discovery efforts as well as analytical and process development research for drug substance manufacturing in support of clinical trials.

DR. WOLFGANG THIELEMANN,

Head of

After receiving his Ph.D. in Organic Chemistry from the University of Münster, Germany in 1997, Dr Thielemann spent a year as postdoctoral fellow at the University of California, Berkeley. In 1999 he started as medicinal chemist in the Chemical Research Department of Bayer HealthCare. After 3 years of chemical research he moved to the Scientific Information and Documentation department as head of the patent information group, and in 2005 as head of the information retrieval group. After the merger with Schering AG he became head of Information Retrieval and Analysis within the Global Research & Development Information department of Bayer Schering Pharma AG (now Bayer HealthCare Pharmaceuticals). The main focus of his group is the provision of professional in-depth searches and analyses of patent, literature, and pipeline information and the development and implementation of advanced post-processing and text mining technologies.

DR. RICHARD K. HARRISON,

Scientific Director, CMR International, a Thomson Reuters Business

Dr. Richard K. Harrison has over 30 years of experience in the life sciences industry, focusing on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont, and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects. He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities. Today he is Scientific Director at CMR International, a Thomson Reuters business.